ABBV-744

• CAT Number: I013997
• CAS Number: 2138861-99-9
• Molecular Formula: C28H30FN3O4
• Molecular Weight: 491.55
• Purity: ≥95%
• Target: BDII-selective BET bromodomain inhibitor
• Solubility: DMSO

ABBV-744 (CAT: I013997) is an investigational small molecule compound developed by AbbVie, a pharmaceutical company. It is a selective inhibitor of the bromodomain and extra-terminal (BET) proteins, specifically targeting bromodomain-containing protein 4 (BRD4). ABBV-744 modulates the activity of BRD4, which plays a role in regulating gene expression and cellular signaling pathways. Preclinical studies suggest that ABBV-744 may have therapeutic potential in the treatment of various cancers, including hematological malignancies and solid tumors. By inhibiting BRD4, ABBV-744 aims to disrupt oncogenic signaling, inhibit tumor growth, and potentially overcome resistance to existing therapies. However, it’s important to note that ABBV-744 is still under investigation and further clinical trials are needed to evaluate its safety and efficacy in human patients.

Reference

[1]FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1.